Company:  CYTRX CORP (CYTR)
Form Type:  10-Q
Filing Date:  11/9/2012 
CIK:  0000799698 
Address:  11726 SAN VICENTE BOULEVARD
SUITE 650
 
City, State, Zip:  LOS ANGELES, California 90049 
Telephone:  310-826-5648 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$3.18  
Change: 
0.035 (1.11%)  
Trade Time: 
Apr 24  
Market Cap: 
$176.69M
Description of Business
References in this Annual Report to the �company,� �we,� �us� or �our� refer to CytRx Corporation, unless otherwise indicated. COMPANY OVERVIEW We are a biopharmaceutical research and development company specializing in oncology. We currently are focused on the clinical development of aldoxorubicin (formerly known as INNO-206), our modified version of the widely-used chemotherapeutic agent, doxorubicin. We recently reported top-line efficacy results (median progression-free survival, progression-free survival at six months, overall response rates and hazard ratios) of our Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcoma, or STS. Hazard ratios - the likelihood that the study endpoint (in this case tumor progression) will be reached during a given period - are an important measure of the reliability and uniformity of the absolute data for progression-free survival, or PFS.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. - Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO CONDENSED FINANCIAL STATEMENTS
      Item 2. - Management's Discussion and Analysis of Financial ...
      Item 3. - Quantitative and Qualitative Disclosures About ...
      Item 4. - Controls and Procedures
    PART II - OTHER INFORMATION
      Item 6. - Exhibits
    SIGNATURES
    INDEX TO EXHIBITS
  EXHIBIT 31.1
    CERTIFICATIONS
  EXHIBIT 31.2
    CERTIFICATIONS
  EXHIBIT 32.1
  EXHIBIT 32.2
    Certification of Chief Financial Officer
BROKERAGE PARTNERS